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Abstract
MEDI-565 (also known as MT111) is a bispecific T-cell engager (BiTEH) antibody in development for the treatment of patients
with cancers expressing carcinoembryonic antigen (CEA). MEDI-565 binds CEA on cancer cells and CD3 on T cells to induce
T-cell mediated killing of cancer cells. To understand the molecular basis of human CEA recognition by MEDI-565 and how
polymorphisms and spliced forms of CEA may affect MEDI-565 activity, we mapped the epitope of MEDI-565 on CEA using
mutagenesis and homology modeling approaches. We found that MEDI-565 recognized a conformational epitope in the A2
domain comprised of amino acids 326–349 and 388–410, with critical residues F
326,T
328,N
333,V
388,G
389,P
390,E
392,I
408, and
N
410. Two non-synonymous single-nucleotide polymorphisms (SNPs) (rs10407503, rs7249230) were identified in the epitope
region, but they are found at low homozygosity rates. Searching the National Center for Biotechnology Information
GenBankH database, we further identified a single, previously uncharacterized mRNA splice variant of CEA that lacks a
portion of the N-terminal domain, the A1 and B1 domains, and a large portion of the A2 domain. Real-time quantitative
polymerase chain reaction analysis of multiple cancers showed widespread expression of full-length CEA in these tumors,
with less frequent but concordant expression of the CEA splice variant. Because the epitope was largely absent from the
CEA splice variant, MEDI-565 did not bind or mediate T-cell killing of cells solely expressing this form of CEA. In addition, the
splice variant did not interfere with MEDI-565 binding or activity when co-expressed with full-length CEA. Thus MEDI-565
may broadly target CEA-positive tumors without regard for expression of the short splice variant of CEA. Together our data
suggest that MEDI-565 activity will neither be impacted by SNPs nor by a splice variant of CEA.
Citation: Peng L, Oberst MD, Huang J, Brohawn P, Morehouse C, et al. (2012) The CEA/CD3-Bispecific Antibody MEDI-565 (MT111) Binds a Nonlinear Epitope in
the Full-Length but Not a Short Splice Variant of CEA. PLoS ONE 7(5): e36412. doi:10.1371/journal.pone.0036412
Editor: Aleksey Porollo, University of Cincinnati College of Medicine, United States of America
Received December 6, 2011; Accepted April 9, 2012; Published May 4, 2012
Copyright:  2012 Peng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: P. Baeuerle is an employee of Micromet, Inc. All other authors are employees of MedImmune LLC. MedImmune and Micromet have
several patent applications pending relating to MEDI-565 (a product in development). This does not alter the authors’ adherence to all the PLoS ONE policies on
sharing data and materials, as detailed online in the guide for authors.
* E-mail: damschroderm@medimmune.com (MD); hammonds@medimmune.com (SH)
. These authors contributed equally to this work.
Introduction
Carcinoembryonic antigen (CEA; CEACAM5; CD66e) is a
glycosylated human oncofetal antigen that belongs to the CEA-
related cell adhesion molecule (CEACAM) family of the immu-
noglobulin (Ig) gene superfamily [1,2]. CEA is closely related to
CEACAM1, CEACAM3, CEACAM4, CEACAM6, CEACAM7,
and CEACAM8. Carcinoembryonic antigen has been suggested to
mediate cell-cell adhesion, facilitate bacterial colonization of the
intestine, and protect the colon from microbial infection by
binding and trapping infectious microorganisms [3].
CEA is expressed at low levels in normal tissues of epithelial
origin in a polarized manner; found only at the luminal portion of
the cell but not at the basolateral surface [3]. In contrast,
expression of CEA is frequently high in carcinomas, including
colon, pancreatic, gastric, esophageal, lung, breast, uterine,
ovarian, and endometrial cancers [3]. Cancer cells not only lose
polarized (luminal) expression of CEA, but actively cleave CEA
from their surface by phospholipases, an action that results in
serum concentrations of CEA that can approach 5 mg/mL [3,4,5].
Serum CEA levels may be monitored to detect a response to anti-
cancer therapy, or disease recurrence in colorectal cancer [6], and
serves as a prognostic indicator in patients with gastrointestinal
cancers, where elevated levels indicate a poor prognosis and
correlate with reduced overall survival [7,8,9].
Cell-bound CEA has served as a target for tumor imaging and
anti-cancer therapies. Clinical studies have demonstrated that
radiolabeled anti-CEA antibodies and antibody fragments, such as
the Food and Drug Administration-approved, Tc-99m-labeled,
anti-CEA Fab arcitumomab (CEA-ScanH), can be successfully
used as imaging reagents to specifically localize CEA-expressing
solid cancers [10,11,12]. Anti-CEA radio-immunoconjugate anti-
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treatment of patients with metastatic colorectal cancer [13]. In
addition, CEA-specific antibody-directed enzyme prodrug therapy
and CEA-based vaccine approaches have been developed to treat
cancers [14,15].
As a novel CEA-directed therapy, we have developed a CEA-
targeting bispecific single-chain antibody of the bispecific T-cell
engager (BiTE) class termed MEDI-565 (also known as MT111)
[16,17,18]. BiTE antibodies are a unique subclass of bispecific
antibodies that contain one single chain variable fragment (scFv)
with specificity for a tumor associated antigen molecularly fused to
another scFv with specificity for CD3 on T cells [19]. Highly
potent and specific tumor cell lysis is triggered only when BiTE
antibodies bind both epitopes simultaneously, resulting in directing
T cells to the tumor cells and activating the T cell through the
CD3/T cell receptor (TCR) complex [20]. Notably, activation of
T cells is independent of TCR specificity, peptide antigen
presentation, and co-stimulatory signals [21]. As a result of T
cell activation, granzymes and perforin are mobilized to the tumor
cell-T cell interface and mediate an apoptotic killing of target cells;
FAS ligand expression may also contribute to the induction of
apoptosis through engagement of FAS on tumor cells [22,23,24].
BiTE antibodies activate both CD4+ and CD8+ T cell subsets
[23,25,26,27,28]; both subsets of T cells contribute to tumor cell
killing at relatively low effector T cell:target tumor cell (E:T) ratios
[22,29]. Cytokine secretion and the upregulation of cell surface IL-
2 receptor by T cells (measured experimentally using antibodies
recognizing the IL-2Ra chain/CD25) occur simultaneously and
accompany tumor cell killing [18,22,25]. Both potentiate further T
cell activation and proliferation, facilitating the subsequent
engagement and killing of additional tumor cells bound by a
BiTE antibody. BiTE antibodies not only induce the potent lysis of
human cancer cell lines in vitro, but have also been shown to
mediate the killing of primary human tumor cells by cancer
patient T cells ex vivo [17,25,30]. Furthermore, BiTE antibodies
promote in vivo tumor regression in numerous pre-clinical animal
models [16,31,32,33,34,35,36] and have shown signs of clinical
benefit in patients with cancer [37,38,39].
MEDI-565 itself is composed of a humanized single-chain
antibody recognizing human CEA connected by a short flexible
linker to a de-immunized single-chain antibody specific for CD3,
and shares the characteristics of the BiTE antibody class as
described above [16,17,18]. It specifically binds to CEA and not to
other CEACAM family members [16]. Upon concurrent binding
to CEA on cancer cells and CD3 on T cells, MEDI-565 mediates
T cell activation and the subsequent killing of CEA-expressing
target cells in a perforin- and granzyme-dependent manner that is
insensitive to concentrations up to 5 mg/mL of soluble CEA
[16,17,18]. Furthermore, intravenous and subcutaneous adminis-
tration of MEDI-565 had anticancer activity in severe combined
immunodeficient mouse xenograft models of various human
cancers [18]; growth inhibition of the cancers was contingent on
both the presence of un-stimulated human T cells and the
expression of CEA on the cancer cells [18]. MEDI-565 is currently
in phase I clinical trials (clinicaltrials.gov identifier:
NCT01284231) for the treatment of gastrointestinal adenocarci-
nomas.
To understand the molecular basis of human CEA recognition
by MEDI-565 and the impact of amino acid polymorphisms and
splice variants of CEA on the activity of MEDI-565, we sought to
identify the CEA domain and the critical residues involved in
MEDI-565 binding. The CEA-specific arm of MEDI-565 is a
humanized version of the murine antibody A5B7 [40,41] the
binding epitope of which is unknown [40,42]. We mapped its
epitope using mutagenesis and computational modeling approach-
es. We further investigated what impact a CEA splice variant
which lacks a large portion of the identified epitope could have on
the binding and activity of MEDI-565.
Materials and Methods
Vectors Expressing Full-length and Splice Variant CEA
The plasmid containing the full-length CEA sequence was
purchased from Open Biosystems (Thermo Fisher Scientific,
Huntsville, AL). The CEA complementary DNA (cDNA) was sub-
cloned using sequence specific primers into a modified version of
the lentiviral vector pCDH1-CMV-MCS-EF1-Puro (System Bio-
sciences, Mountain View, CA) in which the puromycin-resistance
casette was replaced with a blasticidin-resistance cassette (pCDH1-
CMV-MCS-EF1-Blast) and the CEA sequence was verified by
DNA sequencing. The plasmid containing the sequences of the
CEA splice variant (cDNA clone DKFZp781M2392) was
purchased from ImaGenes GmbH (Source BioScience UK
Limited, Nottingham, UK) in association with B Bridge Interna-
tional (Cupertino, CA). The CEA splice variant was cloned into
the puromycin resistance lentiviral vector pCDH1-HCS1-EF1-
Puro (System Biosciences) using sequence-specific primers and the
resulting clones were sequence-verified.
Cell Culture, Antibodies, and Reagents
FreeStyle human embryonic kidney (HEK293) F cells (Amer-
ican Type Culture Collection, Manassas, VA) were cultured in
FreeStyle 293 expression medium (Life Technologies/Invitrogen,
Carlsbad, CA). Dihydrofolate reductase deficient (DHFR-) Chi-
nese hamster ovary (CHO) cells or CHO DHFR- cells (American
Type Culture Collection, Manassas, VA) were cultured in RPMI
1640 media (Invitrogen) containing 10% fetal bovine serum (FBS;
Invitrogen) in a humidified cell culture incubator at 37uC and 5%
CO2. CHO cells expressing the CEA splice variant (CHO SV
CEA) were created by infection of CHO DHFR- cells with the
pCDH1-HCS1-EF1-Puro-CEA splice variant lentiviral vector,
and selected by culturing in medium containing 5 mg/mL
puromycin (EMD Chemicals Group, Merck KGaA, Darmstadt,
Germany) for 72 hours. CHO cells expressing the full-length CEA
sequence (CHO FL CEA) were created by infecting CHO DHFR-
cells with the lentiviral expression vector pCDH1-CMV-MCS-
EF1-Blast-CEA, and selected by culturing in medium containing
10 mg/mL blasticidin (Invitrogen) for 10 days. Likewise, cells
expressing both the CEA splice variant and full-length CEA (CHO
FL+SV CEA) were created by infecting CEA splice variant-
expressing cells with the pCDH1-CMV-MCS-EF1-Blast-CEA
lentiviral vector followed by blasticidin selection. The anti-
CEACAM5 specific monoclonal antibody (mAb) clone 26/3/13
was purchased from Genovac GmbH (Aldevron, Freiburg,
Germany). Propidium iodide (PI) was purchased from Sigma-
Aldrich (St. Louis, MO). Construction and production of MEDI-
565 and the Control BiTE (MEC14 BiTE) has been described
[17].
Primary Pancreatic Tumor Tissues
Twenty pancreatic primary tumors were purchased from
Asterand, Inc (Detroit, MI). The panel included 13 adenocarci-
nomas (stage I-IV), 5 pancreatic endocrine tumors and 2 benign
pancreatic adenomas. Four of the 20 pancreatic tumor tissue
samples had matched normal adjacent pancreatic tissue samples.
Patient age ranged from 23 to 77 years. All samples were freshly
frozen and collected before the initiation of any cancer treatment.
Tumor samples were macrodissected to remove normal tissue, and
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were macrodissected to remove non-glandular tissue.
Cancer Tissue cDNA Arrays
Cancer tissue cDNA arrays: HCRT101 (Colon Cancer),
HGRT101 (Gastroesophageal Cancer), PNRT101 (Pancreatic
Cancer), HLRT101 (lung cancer), and BCRT101 (breast cancer)
were purchased from OriGene Technologies (Rockville, MD).
Each array contains cDNAs from 5 to 8 normal tissues and 19 to
42 cancer tissues. The tumor stage ranged from stage I to IV and
the tumor tissues were comprised of 50–90% tumor.
Western Blotting
Cells were lysed in RIPA lysis buffer (Boston Bioproducts,
Ashland, MA) and the resulting protein was quantified using the
BCA protein assay kit (Thermo Fisher Scientific, Huntsville, AL).
Cell lysates were mixed with NuPAGEH LDS 4X LDS sample
buffer (Invitrogen) to 1X concentration; ten micrograms of total
protein from each lysate was analyzed on a pre-cast NuPAGEH
NovexH 10% polyacrylamide Bis-Tris gel (Invitrogen) together
with the NovexH Sharp Pre-stained Protein Standard (Invitrogen)
using NuPAGEH Tris-acetate SDS running buffer (Invitrogen).
Protein from each gel was transferred to a polyvinylidene fluoride
membrane using an iBlotH Dry Blotting System (Invitrogen) and
2X NuPAGEH transfer buffer (Invitrogen) containing 20%
methanol and blocked with 3% bovine serum albumin (Sigma)
in PBS pH 7.4 (Invitrogen). To detect CEA, each blot was probed
overnight with 1 mg/mL of the CEACAM5-specific mAb clone
26/3/13 (Genovac), washed with PBS pH 7.4 containing 0.1%
Tween-20, and subsequently probed for 1 hour with a horseradish
peroxidase-conjugated donkey anti-mouse IgG secondary anti-
body (Jackson ImmunoResearch Laboratories, West Grove, PA).
After 5 washes with PBS pH 7.4 containing 0.1% Tween-20, each
blot was exposed to SuperSignal West Pico Chemiluminescent
Substrate (Thermo Fisher Scientific) and exposed to BioMax MS
Kodak film (Sigma) for detection of chemiluminescence resulting
from bound anti-CEACAM5 antibody. Equal amounts of protein
loaded into each lane of the gel were controlled by detecting the
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) protein
using a rabbit anti-human GAPDH polyclonal antibody (Trevi-
gen, Gaithersburg, MD) followed by a horseradish peroxidase-
conjugated donkey anti-rabbit IgG (Jackson ImmunoResearch).
Generation and Characterization of Deletion and Swap
Mutants of CEA
The cDNA encoding the CEA deletion variants DelA1-A2, Del
A1, DelB1, DelA2, and DelB2-A3 and the swap variants KO_A,
KO_B, KO_C, KI_A, KI_B, and KI_C (see Figures 1, 2, 3, and 4
for domain definition and variant nomenclature) were assembled
and amplified by overlapping extension polymerase chain reaction
(PCR) using an in-house full-length CEA cDNA clone, pNEO
human CEA-GPI, as a template. The CEA variants and the full-
length CEA cDNA were cloned into a mammalian expression
vector pcDNA3.1 (Invitrogen).
Expression vectors encoding the CEA deletion and swap
mutants were transiently transfected for expression of glycopho-
sphatidyl inositol (GPI)-anchored proteins using FreeStyle
HEK293 F cells (Invitrogen). One day prior to transfection,
HEK293 F cells were seeded at a density of 0.7610
6 cells/mL.
Three and a half micrograms of each expression vector were
transfected into 5 mL of a suspension of HEK293 F cells using
5 mL of 293fectin transfection reagent (Invitrogen). Transfected
cells were incubated with 5 mg/mL of MEDI-565 for 1 hour. For
the detection of bound MEDI-565, which possesses a six-histidine
tag at its carboxy-terminus, the cells were washed three times with
PBS and incubated with 1 mg/mL of an Alexa FluorH 488-
conjugated anti-penta-His antibody (Qiagen, Valencia, CA) for 30
minutes, and then analyzed for binding using the LSRII flow
cytometer (BD Biosciences, San Jose, CA). Expression of CEA
deletion mutants was monitored with a goat anti-CEA polyclonal
antibody (R&D Systems, Minneapolis, MN) that was detected by
an R-phycoerythrin-conjugated anti-goat IgG (Invitrogen).
Site-directed Mutagenesis and Computational Homology
Modeling
Site-directed mutagenesis and computational homology model-
ing were implemented to identify amino acids within CEA that are
critical for MEDI-565 binding. The following amino acids in the
epitope-containing segments A and C of the A2 domain (see
Results and Discussion section) that differ from those in the A3
domain were mutated in clusters or individually to encode the
corresponding amino acids of the A3 domain: F
326T
328N
333
(KO_FTN), N
333E
338 (KO_NE), N
333 (KO_N), E
338L
343I
349
(KO_ELI), V
388G
389P
390E
392 (KO_VGPE),
E
398L
399V
401D
402H
403 (KO_ELVDH), and I
408N
410 (KO_IN).
A modeled structure of the A2 domain of CEA was constructed
using SWISS-MODEL workspace [43] and the crystal structure of
mouse CEACAM1A (33.7% sequence identity with mature
human CEA protein, NCBI accession number NP_001020083.1,
Protein Data Bank accession number 1L6Z) [44]. This model was
used as a template to engineer two additional mutants. These two
mutants 1) substituted clusters V
388G
389P
390E
392 and I
408N
410 of
the A2 domain with the corresponding clusters of the A3 domain
(KO_VGPE+IN), and 2) grafted clusters F
326T
328N
333,
V
388G
389P
390E
392, and I
408N
410 of the A2 domain into the A3
domain (KI_FTN+VGPE+IN), respectively. All mutants were
assembled by overlapping extension PCR using the truncated
mutants A2 or A3 as a template, which encodes for the N-terminal
domain, the A2 or A3 domain, and the GPI region. They were
cloned into the mammalian expression vector pcDNA3.1 (Invitro-
gen). Expression of these mutants and binding analyses were
conducted as listed above for the deletion and swap mutants.
Design of Real-time Quantitative PCR Primer and Probes
for Full-length and Splicing Variant of CEA
Full-length mRNA transcript sequences for CEA
(NM_004363.2) and the CEA splice variant (DKFZp781M2392)
were retrieved from the NCBI Reference Sequences database. For
the full-length CEA assay we targeted the splice junctions of exons
3 and 4 to design the gene specific probe. For the CEA splice
variant assay we targeted the splice junctions of exons 2 and 5
exon to design the gene specific probe. All primer/probes were
imported into the Primer Express (Applied Biosystems, Foster
City, CA) software tool to ensure the optimal design for utilization
in the TaqMan Gene Expression assay procedure. All probes were
designed to incorporate a minor groove binding moiety (MGB),
and were labeled with a fluorescent dye (FAM) for detection and as
a non-fluorescent quencher. Primers and probes were custom
ordered from Applied Biosystems. Sequences for all primer/probe
combinations are as follows:
CEA full-length: The sequence of the probe is 59-CAGGCG-
CAGTGATTCA-39.
The sequence of the forward primer 59-GAAACCCAGAACC-
CAGTGAGT- 39.
The sequence of the reverse primer is 59 GCCATAGAGGA-
CATTCAGGATGAC-39.
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ATGCATCCCTGCTGATCC-39.
The sequence of the forward primer is 59-CGCATA-
CAGTGGTCGAGAGATAATA-39.
The sequence of the reverse primer is 59-CGCTGTGGTCAA-
CACTTAATTTGT-39.
Real-Time Quantitative PCR from Frozen Pancreatic
Tissue Specimens
Real-time qPCR was conducted with the BioMark
TM
Dynamic Array Microfluidics System (Fluidigm Corporation,
South San Francisco, CA) using RNA isolated from frozen
pancreatic tissues. First, total RNA was extracted from frozen
slide sections of pancreatic tissue classified as normal (NAT,
normal adjacent to tumor), adenocarcinoma, benign adenoma,
or endocrine tumor using the ZR RNA MicroPrep kit (Zymo
Research, Orange, CA). RNA purity and concentration were
determined spectrophotometrically. RNA quality was assessed
on an Agilent 2100 Bioanalyzer using the RNA 6000 Nano
LabChipH (Agilent Technologies, Santa Clara, CA). Single
stranded cDNA was generated from total pancreas RNA using
the SuperScriptH III First-Strand Synthesis SuperMix (Invitro-
gen). cDNA samples were pre-amplified using TaqMan Pre-
Amp Master Mix (Invitrogen), according to the manufacturer’s
instructions. Reactions were cycled with the recommended
program for 14 cycles and then diluted 1:5 with TE buffer. Pre-
amplified cDNA was either utilized immediately or stored at
220uC until processed. Samples and TaqMan Gene Expression
assays (Applied Biosystems, Carlsbad, CA) were load onto a
96.96 dynamic array (Fluidigm) according to the manufacturer’s
instructions. The prepared array was loaded on the BioMark
TM
Real-Time PCR System (Fluidigm) for thermal cycling (10 min
at 95uC followed by 40 cycles of 95uC for 15 sec and 1 min at
60uC). Upon completion of the qPCR, Fluidigm Real-Time
PCR Analysis software was used to generate threshold cycle (Ct)
values. A Ct cutoff value of 24, below which the samples were
considered to be positive and above which the samples were
considered to be negative for transcript expression, was
empirically selected.
Real-Time Quantitative PCR from Tissue cDNA Arrays
TissueScan
TM Disease Tissue quantitative polymerase chain
reaction (qPCR) arrays (Origene Technologies, Rockville, MD)
were employed to determine the expression of full-length and
CEA splice variant (SV) transcripts in normal and cancerous
tissues of various stages and grades. For each tissue cDNA array,
lyophilized cDNA was resuspended in 2.5 mL of ribonuclease-free
water. Plates were sealed, vortexed, and centrifuged (1200 g for
1 min) to ensure resuspension of the full cDNA sample. A 0.2X
mixture of the TaqMan assays (Applied Biosystems) was then
created according to protocols supplied by the manufacturer for
pre-amplification (one cycle of 95uC, 10 min followed by 14
cycles of 95uC 15 sec/60uC 4 min). Subsequent amplification
and transcript detection (one cycle of 95uC, 20 sec followed by
40 cycles of 95uC, 1 sec/60uC, 20 sec) of the specific target
transcripts was carried out using an ABI 7900HT Fast Real
Time PCR Instrument (Applied Biosystems). Upon completion of
the qPCR, SDS 2.2 Software (Ericsson, Stockholm, Sweden) was
used to generate threshold cycle (Ct) values. A Ct cutoff value of
30, below which the samples were considered to be positive and
above which the samples were considered to be negative for
transcript expression, was empirically selected. As positive
controls, cDNAs from CHO cells expressing either full-length
CEA (CHO FL CEA) or the CEA splice variant (CHO SV CEA)
were used. Complementary DNA isolated from DHFR-deficient
CHO cells lacking CEA expression was used as a negative
control for qPCR.
Figure 1. Schematic representations of the full-length CEA and CEA splice variant. A, intron and exon structure of the full-length CEA and
CEA splice variant transcripts. The full-length CEA transcript (NCBI accession number NM002483) consists of 10 exons and 9 introns as shown
schematically. The transcript corresponding to the CEA splice variant (NCBI accession number CR749337) removes exons 3 and 4 and a portion of
exon 2 to create an alternative splice variant CEA transcript with 8 exons and 7 introns. Boxes indicate exons and lines indicate introns (not drawn to
scale). B, protein domain structure of the translated full-length and splice variant transcripts of CEA. The mature full-length CEA is composed of one
N-terminal domain and six IgC-like domains denoted A1, B1, A2, B2, A3, and B3. The gray bar represents the GPI linkage of the proteins to the plasma
membrane shown as two parallel vertical black lines.
doi:10.1371/journal.pone.0036412.g001
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For binding studies with MEDI-565, Control BiTE (bispecific
single-chain antibody specific for the herbicide mecoprop and
human CD3; also known as MEC14 BiTE), anti-CEACAM5 mAb
clone 26/13/3 (Genovac), or control mouse IgG1 (BioLegend, San
Diego, CA) were used. The antibodies were incubated with CHO
cells at a concentration of 10 mg/mL diluted in PBS/2% FBS for
20 minutes at 4uC. For the detection of bound MEDI-565 and
Control BiTE, the CHO cells were washed three times with PBS/
2% FBS and incubated with 4 mg/mL of an AlexaFluorH 488-
conjugated anti-penta-His antibody (Qiagen) in PBS/2% FBS for
15 minutes at 4uC in the dark. For the detection of bound anti-
CEACAM5 and control IgG mAbs, CHO cells were washed three
times with PBS/2% FBS and incubated with 10 mg/mL of an
Alexa FluorH 488-conjugated goat anti-mouse IgG (Invitrogen) in
PBS/2% FBS for 15 minutes at 4uC in the dark. All CHO cells
were washed one time with PBS/2% FBS, resuspended in PBS/
2% FBS containing 10 mg/mL of PI and the fluorescence
intensities of bound secondary antibodies were detected by flow
cytometry using an LSRII flow cytometer (BD Biosciences); the
data were analyzed using FlowJo Software (Treestar, Ashland,
OR). Viable CHO cells (PI negative) were examined for the
fluorescence intensities of bound secondary antibodies. Non-linear
regression analyses employing one-site saturation binding models
using mean fluorescent intensity values of antibody binding to
CEA-expressing cells were performed using GraphPad Prism
software version 5.01 for Windows (GraphPad Software, San
Diego, CA.) to determine apparent equilibrium binding constants
(apparent KD values) of MEDI-565 binding to CEA.
Figure 2. Amino acid sequence alignment of the full-length CEA (Swiss-Prot P06731-1) and CEA splice variant proteins. Amino acids
corresponding to the signal peptide, the six IgC-like domains, and the C-terminal peptide which is removed during the protein maturation process
are over-lined with alternating solid or dashed lines. The epitope regions (aa 326–349 and 388–410) are enclosed by black boxes. The critical aa N
333
involved in MEDI-565 binding is labeled with an arrowm. Two polymorphisms in the epitope region are marked with a diamond¤ (rs10407503; aa
change Ala R Asp) and a circleN (rs7249230; aa change Glu R Lys).
doi:10.1371/journal.pone.0036412.g002
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MEDI-565 induced T-cell killing of CHO DHFR-, CHO FL
CEA, CHO SV CEA and CHO FL+SV CEA cells was
determined using a flow cytometry-based assay that measures
the viability of dye-labeled target cells. Human CD3+ T cells were
enriched from heparinized whole blood PBMCs of healthy donors
by the RosetteSepH human T-cell enrichment cocktail (Stem Cell
Technologies, Vancouver, BC, Canada) and RosetteSep T-cell
density medium (Stem Cell Technologies) according to the
manufacturer’s protocol. CHO DHFR-, CHO FL CEA, CHO
SV CEA and CHO FL+SV CEA cells were used as target cells,
and labeled with 3,39-dioctadecyloxacarbocyanine perchlorate
(DiO) cell labelling solution (Invitrogen) to distinguish them from
effector T cells during flow cytometry analysis. Enriched CD3-
positive T cells and DiO-labeled CHO cells were suspended in
RPMI-1640 medium (Invitrogen) containing 10% FBS and 4.5 g/
L glucose. Serial dilutions of MEDI-565 or Control BiTE
(containing an scFv recognizing the herbicide mecoprop in place
of the CEA-binding scFv) were added to target and effector cells in
96-well non-tissue culture treated plates (Corning, Corning, NY) at
an effector-to-target ratio of 10:1. The co-cultures were incubated
at 37uC in a humidified tissue culture chamber with an
atmosphere of 5% CO2 for 48 hours. Cytotoxicity, defined as a
loss of cell membrane integrity, was monitored by cellular uptake
of Propidium Iodide (PI); live cells exclude PI while dead cells do
not. An LSRII flow cytometer using FACSDiva software (BD
Biosciences) was used to collect data and FlowJo software
(Treestar) was used to analyze the data. Cytotoxicity (specific
lysis) was calculated as the percentage of all DiO-labeled target
cells identified as nonviable in each well, minus background values
calculated from wells containing target cells and T cells without
MEDI-565. Non-linear regression analyses using a four-parameter
fit were performed with GraphPad Prism software version 5.01 for
Windows (GraphPad Software) to generate sigmoidal dose-
response curves and determine calculated half-maximal effective
concentrations (EC50) values. Sigmoidal dose response curves
typically had R
2 values .0.90, and EC50 values were used for
comparison of bioactivity. CD8+ and CD4+ T cells were
subdivided using a PECy7-conjugated mouse anti-human CD8
mAb and a V450-conjugated mouse anti-human CD4 mAb (BD
Biosciences). T-cell activation (CD25 up-regulation) was moni-
tored by the allophycoerytherin (APC)-conjugated mouse anti-
human CD25 mAb (Becton Dickinson Biosciences).
To measure the killing of human tumor cell lines by MEDI-565
or the control BiTE, cell lines were co-cultured with enriched
CD3+ T cells and BiTE antibody as described above, and cell lysis
was measured by the release of caspase-3 into the tissue culture
media via a caspase-3 specific electrochemiluminescence assay
(Meso Scale Discovery, Gaithersburg, MD).
Statistical Analyses
The statistical significance of differences in affinity (apparent
KD) and cytotoxicity (EC50) values was calculated using two-tailed,
parametric t tests calculated in GraphPad Prism software version
5.01 for Windows (GraphPad Software).
Results
MEDI-565 Binds a Nonlinear Epitope in the A2 Domain of
CEA
MEDI-565 recognizes full length CEA; however, the corre-
sponding epitope is unknown. CEA deletion mutants were
generated to identify the domain of CEA to which MEDI-565
binds. The full-length CEA transcript (NCBI accession number
Figure 3. Deletion mutants of human CEA. A, linear display of the modular structures of human CEA and deletion mutants. Five deletion
mutants were constructed by removing individual IgC-like domains as denoted in their name. B, flow cytometry analysis of binding of MEDI-565 to
deletion mutants expressed on the surface of HEK293 F cells. All mutants were expressed well as monitored by an anti-CEA polyclonal antibody.
MEDI-565 did not recognize any of the deletion mutants which lack the A2 domain (DelA1-A2 and DelA2), but bound well to all mutants which are
comprised of the A2 domain (DelA1, DelB1 and DelB2-A3).
doi:10.1371/journal.pone.0036412.g003
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amino acid (aa) protein composed of a 34 aa processed leader
sequence, one IgV-like N-terminal domain, six immunoglobulin
constant (IgC)-like domains denoted A1, B1, A2, B2, A3 and B3,
and a C-terminal 17 aa peptide which is removed during GPI
linkage [1,2,45,46] (Figure 1, 2). Five deletion mutants were
constructed by removing the following IgC-like domains: A1, B1
and A2 domains (DelA1-A2), A1 domain (DelA1), B1 domain
(DelB1), A2 domain (DelA2), and B2 and A3 domains (DelB2-A3)
as shown in Figure 3A. The mutants were transiently expressed as
GPI-anchored proteins on HEK293 F cells. The binding of
MEDI-565 or the anti-CEA polyclonal control antibody to each of
the deletion mutants was analyzed using flow cytometry. MEDI-
565 did not recognize any of the deletion mutants which lack the
A2 domain (DelA1-A2 and DelA2, Figure 3B), but bound well to
all mutants that contained it (DelA1, DelB1 and DelB2-A3,
Figure 3B). Additionally, when all but the A2 IgC-like domains
were removed (A2; Figure 4B), MEDI-565 still recognized the
corresponding truncated CEA protein at a level similar to that
measured for full-length CEA protein (Figure 4C). These results
suggested that the epitope of MEDI-565 is localized in the A2
domain of CEA.
The A3 domain is not involved in MEDI-565 binding despite
being highly homologous with the epitope-containing A2 domain;
therefore, swap-mutants were constructed by exchanging short
segments of the A2 domain with the corresponding portions of the
A3 domain to further refine the MEDI-565 binding epitope. Two
truncated CEA mutants (A2 and A3) were engineered and used as
templates for the construction of swap mutants. The A2 or A3
mutant is comprised of the N-domain, the A2 or A3 domain, and
the GPI region. An alignment of the amino acid sequences of the
A2 and A3 domains identified differences in their aa composition.
These regions of sequence diversity were divided into three shorter
segments labeled as A (aa 326 to 349), B (aa 360 to 382) and C (aa
388 to 410) (Figure 4A). Six swap mutants were generated by
swapping segments A, B or C of the A3 domain into the A2
domain (KO mutants), or by swapping segments of the A2 domain
into the A3 domain (KI mutants) as shown in Figure 4B. MEDI-
565 did not bind to any of the KO or KI mutants lacking either
the A or C segment of the A2 domain (KO_A, KO_C, KI_A,
KI_B and KI_C, Figure 4B, C), but bound well to the swap
variant which encoded both the A and C segments of the A2
domain (KO_B, Figure 4B, C). Some residual binding of MEDI-
565 to the KO_C mutant could be detected. Together with
Figure 4. Swap-mutants of human CEA. A, amino acid sequence alignment of the A2 and A3 domains of CEA. Sequence homology analysis
revealed 21 amino acids that differed between these two domains (amino acids boxed). Three segments, A, B, and C, were defined in the A2 and A3
domains to generate swap-mutants. B, a schematic display of swap mutants that were constructed by exchanging segments A, B, or C between the
A2 (open boxes) and A3 (grey boxes) domains using the truncated mutant A2 or A3 as a template which encodes the N-domain, the A2 or A3
domain, and the GPI region. C, flow cytometry analysis of binding of MEDI-565 to deletion mutants expressed on the surface of HEK293 F cells. All
mutants were expressed well as monitored by anti-CEA polyclonal antibody. MEDI-565 did not bind well to any of the knock-out (KO) or knock-in (KI)
mutants which lack either the A or C segment of the A2 domain (KO_A, KO_C, KI_A, KI_B and KI_C), but bound well to the one variant which encoded
both the A and C segments of the A2 domain (KO_B).
doi:10.1371/journal.pone.0036412.g004
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that segment C significantly contributed to MEDI-565 binding,
but to a lesser degree than segment A. Due to the high degree of
identity between segment B in the A2 and the A3 domains, direct
involvement of this segment in MEDI-565 binding could not be
entirely ruled out using a swap mutant-based approach. It is
however unlikely for the following reasons 1) MEDI-565 did not
bind to the mutants encoding the B segment of A2 domain in
conjunction with either A or C segment of the A2 domain (KO_A
or KO_C, Figure 4); 2) The binding level of MEDI-565 to the
mutant encoding both the A and the C segments of A2 domain
(KO_B) was comparable to the signal of both the full-length CEA
and the A2 deletion mutant (Figure 4); and 3) The modeled
structure of the A2 domain using murine CEACAM1 as a
template revealed that segment B was spatially distal from critical
residue N
333 (see following section). Therefore, the swap-mutants
revealed that MEDI-565 bound to a nonlinear epitope in the A2
domain of CEA, which is comprised of two segments, namely 326–
349 (segment A) and 388–410 (segment C).
Identification of Critical Residues of CEA that Contribute
to MEDI-565 Binding
Site-directed mutagenesis and computational homology model-
ing were employed to identify critical residues within segments A
and C that are essential for the binding of MEDI-565. The amino
acids of segments A and C of the A2 domain that differed from the
A3 domains were replaced with the corresponding A3 residues
encoding several substitutions at a time: F
326T
328N
333 (KO_FTN),
N
333 E
338 (KO_NE), and E
338L
343I
349 (KO_ELI)
V
388G
389P
390E
392 (KO_VGPE); E
398L
399V
401D
402H
403
(KO_ELVDH) and I
408N
410 (KO_IN) (Figure 4A). The binding
of MEDI-565 was substantially decreased to the variants in which
residue N
333 was mutated (KO_FTN and KO_NE), but bound
well to the other mutants (Figure 5A). Furthermore, replacing only
residue N
333 with either its counterpart residue Lys in the A3
domain (KO_N) or with Ala (N
333 to A) abolished MEDI-565
binding (Figure 5C). Mutating the residue F
326 or T
328 to Ala
substantially decreased the binding of MEDI-565 (F
326 to A, T
328
to A), suggesting that they were also involved in the interaction
with MEDI-565 but to a lesser extent than residue N
333
(Figure 5C). Taken together, our data demonstrated the impor-
tance of F
326,T
328, and N
333. Finally, since E
338 is encoded in the
KO_ELI variant which binds well to MEDI-565, we concluded
that this residue is not energetically involved in MEDI-565
epitope. We had previously noted that grafting only segment A
that includes the F
326,T
328, and N
333 residues of the A2 domain
into the A3 domain (KI_A) did not result in MEDI-565 binding.
This suggested that MEDI-565 binding epitope comprises
additional critical residues and pointed towards it being non-
linear and conformational.
The modeled structure of the A2 domain also revealed two
clusters of amino acids V
388G
389P
390E
392 and I
408N
410 in segment
C that were spatially close to the already identified critical residue
N
333 in segment A (Figure 5B). This observation suggested that
these amino acids could contribute to the binding of MEDI-565 in
concert with N
333. Knocking-out amino acids V
388G
389P
390E
392
(KO_VGPE) or I
408N
410 (KO_IN) separately (Figure 5A), or
knocking-in the entire segment C which includes both clusters of
V
388G
389P
390E
392 and I
408N
410 (KI_C) (Figure 4C) had no effect
in abolishing or restoring MEDI-565 binding, respectively.
However, knocking-out these amino acids together reduced (but
did not completely abolish) MEDI-565 binding (KO_VGPE+IN,
Figure 5C). Thus, amino acids V
388,G
389,P
390,E
392,I
408, and
N
410 in segment C of CEA could also be involved in MEDI-565
binding.
It is possible that some knock-out CEA variants exhibited an
incorrect fold in or near the MEDI-565 epitope region, thereby
losing their binding capacity. Therefore, we further confirmed the
potential epitope regions identified with knock-out variants by
using gain of function (knock-in) mutants. Indeed, ‘‘knocking in’’
segments A (326–349) and C (388–410) of the A2 domain into the
A3 domain (KO_B/KI_A+C, KO_B encodes the same amino
acids as KI_A+C) resulted in MEDI-565 binding comparable to
full length CEA (Figure 4C, 5C). Furthermore, only grafting the
three amino acids F
326T
328N
333 of segment A with the six amino
acids V
388G
389P
390E
392 and I
408N
410 of segment C into the A3
domain (KI_FTN+VGPE+IN) also resulted in MEDI-565 binding
comparable to full length CEA (Figure 5C). In summary, these
results demonstrate that the epitope of CEA bound by MEDI-565
is a nonlinear, conformational epitope located in the A2 domain of
CEA; it is comprised of two segments of amino acids 326 to 349
and 388 to 410 with critical amino acids F
326,T
328,N
333,V
388,
G
389,P
390,E
392,I
408, and N
410. The residue N
333 may contribute
more to the binding of MEDI-565, since mutating it alone
completely disrupted the interaction (Figure 5C).
Identification of CEA Variants
MEDI-565 binds to mature full-length CEA. However,
polymorphisms and/or isoforms of CEA may alter the binding
epitope and negatively affect the ability of MEDI-565 to bind.
Once the epitope of CEA bound by MEDI-565 had been
identified, the ability of MEDI-565 to recognize cancerous cells
expressing polymorphisms and isoforms of CEA could be
evaluated.
Polymorphisms of CEA were surveyed using the NCBI single-
nucleotide polymorphism (SNP) database (http://www.ncbi.nlm.
nih.gov/projects/SNP). Two non-synonymous coding SNPs of
CEA (rs10407503, rs7249230) were identified in the binding
epitope of MEDI-565 (shown in Figure 2). The single-nucleotide C
to A change in the SNP rs10407503 resulted in the amino acid
change of Ala to Asp at the aa position 340. The single-nucleotide
A to G change in the SNP rs7249230 encoded an aa change of
Glu to Lys at the aa position 398. According to the SNP database,
the minor allele frequencies in the population for rs10407503 are
0.014,0.267 and minor allele frequencies for rs7249230 are
0.03,0.3 in the population, respectively. However, the minor
allele homozygosity rate for rs10407503 is close to 0 in both
European and Asian populations and is 0.083 in Sub-Saharan
African populations. The minor allele homozygosity rate for
rs7249230 was from 0 to 0.068 in different populations. Since the
homozygosity rates of both SNPs are very low, we anticipated the
identified CEA SNPs to have little or no impact on MEDI-565
binding to CEA for these populations.
In addition, the National Center for Biotechnology Information
(NCBI) GenBankH database (http://www.ncbi.nlm.nih.gov/
genbank) was searched for splice variants of CEA. A single splice
variant (NCBI accession number CR749337) from colon cancer
tissue was identified. This transcript uses an alternative splice
donor site in exon 2 and skips exons 3 and 4; thus, the translation
of the transcript results in a 420 aa protein with an in-frame
truncation from amino acids 116 to 396 of the full-length CEA.
This truncation deletes a small portion of the N-terminal domain,
the entire A1 and B1 domains, and a large portion of the A2
domain (Figure 1, 2). The splice variant sequence codes for the
same 34-aa processed leader sequence and C-terminal 17-aa
peptide which is expected to be removed during GPI linkage in a
similar manner as full-length CEA, and, after undergoing similar
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be a mature, GPI-anchored membrane protein of 369 amino
acids.
Another putative CEA splice variant involving novel splicing of
exons 9, 10 and the intervening intron sequence has been detected
in the peripheral blood of colon cancer patients by reverse
transcription PCR [47]. However, sequences within the middle
part of a 152 bp PCR product (base pairs 26–99) of the putative
CEA isoform isolated from white blood cells did not match any
part of the genomic sequence of CEA. Therefore, this PCR
product more likely represents a PCR artifact and not a real CEA
splice form. Consequently, we did not investigate this putative
CEA splice variant further.
Expression of the CEA Splice Variant Transcript in Normal
and Cancerous Human Tissues
The biological function and distribution of the CEA splice
variant in normal and cancerous tissues is unknown. To determine
the expression frequency of full-length and CEA splice variant
transcripts in normal and cancerous human tissues, real-time
qPCR was performed using both RNA isolated from frozen
primary human pancreatic tissues and cDNA generated from
frozen colorectal, lung, breast and pancreatic tissues purchased in
the form of multi-tissue cDNA arrays. Each analysis used
sequence-specific primers that specifically amplified either full-
length CEA or CEA splice variant sequences.
Results (Table 1) of qPCR analysis using frozen primary
pancreatic tissue specimens demonstrated that full-length CEA
transcript was detected in normal human pancreatic tissues (3 of
4). Among diseased tissue, the full length transcript was found
frequently in pancreatic adenocarcinoma (12 of 13) and less
frequently in benign adenomas (1 of 2) and in pancreatic
endocrine tumors (3 of 5), although the total number of specimens
representing the latter two categories were small. Transcripts of
the CEA splice variant were not detected in normal pancreatic
tissues (0 of 4), benign adenomas (0 of 2) nor in endocrine tumors
(0 of 5), and were rarely detected in pancreatic adenocarcinomas
(1 of 13). Expression of the CEA splice variant transcript in the
single positive adenocarcinoma specimen was concordant with
full-length CEA transcript expression (Table S1).
Results from qPCR analysis using human tissue cDNA arrays
(Table 2) showed that full-length CEA transcript was commonly
detected (Ct#30) in pancreatic adenocarcinomas (4 of 5), colon
(41 of 42), gastroesophageal (38 of 42), lung (39 of 40), and breast
cancers (38 of 41) of various grades and stages. Full-length CEA
transcripts were infrequently detected in pancreatic endocrine
tumors (2 of 14). In normal colon (5 of 5), lung (8 of 8), and
gastroesophageal (6 of 6) tissues, full-length CEA transcripts were
expressed at relatively high levels (Ct,25). In contrast, in normal
Figure 5. Critical amino acids in CEA involved in MEDI-565 binding. A, flow cytometry analysis of binding of MEDI-565 to CEA mutants
targeting amino acids in segments A and C of the A2 domain. MEDI-565 did not bind to the variants in which the N
333 of the A2 domain was mutated
(KO_FTN and KO_NE), but bound well to the other mutants. B, a modeled structure of the A2 domain of CEA revealed two clusters of amino acids
(V
388G
389P
390E
392 and I
408N
410) in segment C (green) that were spatially close to the critical aa N333 (red) in segment A (yellow), while segment B
(cyan) was distal to aa N333. C, binding characteristics of MEDI-565 to CEA mutants with single or combinatorial mutations. Replacing N
333 with Lys
(KO_N) or Ala (N
333 to A) disrupted the binding of MEDI-565 to the A2 domain. Mutating F
326 or T
328 to Ala reduced the binding of MEDI-565 (F
326 to
A, T
328 to A). Knocking-out the amino acids V
388G
389P
390E
392 and I
408N
410 together from the A2 domain also reduced MEDI-565 binding
(KO_VGPE+IN). Grafting of three amino acids F
326T
328N
333 of segment A of the A2 domain in combination with six amino acids V
388G
389P
390E
392 and
I
408N
410 of segment C of the A2 domain into the A3 domain (KI_FTN+VGPE+IN) resulted in MEDI-565 binding to a level comparable to that of the
mutant encoding both segments A and C of the A2 domain together (KO_B/KI_A+C, KO_B encodes the same amino acids as KI_A+C).
doi:10.1371/journal.pone.0036412.g005
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lower levels (25#Ct,30) in most of the samples tested (5 of 7). No
expression (Ct.30) or low level (25#Ct,30) expression of the full-
length CEA transcript was found in normal pancreatic tissues (3 of
4).
Expression (Ct#30) of CEA splice variant transcripts within the
tissue cDNA arrays was found in most colon (41 of 42) and in half
of the tested gastroesophageal cancers (21 of 42). Expression was
also seen in a proportion of lung (12 of 40) and breast cancers (5 of
41) of various grades and stages. Expression of the CEA splice
variant transcript was infrequently found in pancreatic adenocar-
cinomas (1 of 5) and was not found in endocrine pancreatic
cancers (0 of 14). Normal colon (5 of 5) and gastroesophageal (5 of
6) tissues showed CEA splice variant expression, but was absent in
normal pancreas (0 of 4), lung (0 of 8), and breast (0 of 7).
Expression of CEA splice variant transcripts, although found in
fewer tumor samples than full-length CEA transcripts, was always
concordant with expression of full-length CEA transcripts (Table
S1). Thus, expression of the CEA splice variant transcripts varied
in different cancers; however, it was always coexpressed with full-
length CEA transcripts.
Table 1. Percent expression of full-length CEA and CEA splice variant transcripts in primary human tissues determined by qPCR.
Tissue Type Full Length CEA expression CEA splice variant expression
Pancreas, Normal 3/4 (75%) 0/4 (0%)
Pancreas, Benign Adenoma 1/2 (50%) 0/2 (0%)
Pancreas, Adenocarcinoma 12/13 (92%) 1/13 (8%)
Pancreas, Endocrine Tumor 3/5 (60%) 0/5 (0%)
doi:10.1371/journal.pone.0036412.t001
Table 2. Percent expression of full-length CEA and CEA splice variant transcripts determined by qPCR using human tissue cDNA
arrays.
Tissue Type Full Length CEA expression CEA splice variant expression
Pancreas, Normal 3/4 (75%) 0/4 (0%)
Pancreas, Benign Adenoma 1/2 (50%) 0/2 (0%)
Pancreas, Adenocarcinoma 12/13 (92%) 1/13 (8%)
Pancreas, Endocrine Tumor 3/5 (60%) 0/5 (0%)
Colon, normal 5/5 (100%) 5/5 (100%)
Colon, adenocarcinoma 41/42 (98%) 41/42 (98%)
Pancreas, normal 3/4 (75%) 0/4 (0%)
Pancreas, adenocarcinoma 4/5 (80%) 1/5 (20%)
Pancreas, Endocrine Tumor 2/14 (14%) 0/14 (0%)
Gastroesophageal, normal 6/6 (100%) 5/6 (83%)
Gastroesophageal, cancer 38/42 (90%) 21/42 (50%)
Lung, normal 8/8 (100%) 0/8 (0%)
Lung, cancer 39/40 (98%) 12/40 (30%)
Breast, normal 5/7 (71%) 0/7 (0%)
Breast, adenocarcinoma 38/41 (93%) 5/41 (12%)
Tissue Type Full Length CEA expression CEA splice variant expression
Colon, normal 5/5 (100%) 5/5 (100%)
Colon, adenocarcinoma 41/42 (98%) 41/42 (98%)
Pancreas, normal 3/4 (75%) 0/4 (0%)
Pancreas, adenocarcinoma 4/5 (80%) 1/5 (20%)
Pancreas, Endocrine Tumor 2/14 (14%) 0/14 (0%)
Gastroesophageal, normal 6/6 (100%) 5/6 (83%)
Gastroesophageal, cancer 38/42 (90%) 21/42 (50%)
Lung, normal 8/8 (100%) 0/8 (0%)
Lung, cancer 39/40 (98%) 12/40 (30%)
Breast, normal 5/7 (71%) 0/7 (0%)
Breast, adenocarcinoma 38/41 (93%) 5/41 (12%)
doi:10.1371/journal.pone.0036412.t002
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with MEDI-565-induced T-cell Activation and Target Cell
Killing
Although the CEA splice variant was infrequently found in
pancreatic tumors, it was found at a high frequency in colorectal
(98%) and gastroesophageal (50%) cancers, and to a lesser degree
in lung (30%) and breast (12%) tumors. Due to its concordant
expression with full length CEA in human tumors, we sought to
understand the binding of MEDI-565 to the CEA splice variant
and the role that this CEA isoform might play in targeting CEA-
positive tumors. The amino acids in full-length CEA important for
MEDI-565 binding were found to be largely absent in the CEA
splice variant, except amino acids I
408 and N
410 in segment C
(Figure 2). This observation suggested that binding of MEDI-565
to the CEA splice variant was unlikely to occur. To test this
hypothesis, CHO cells were infected with lentivirus constructs
directing the expression of full-length CEA (CHO FL CEA) or the
CEA splice variant (CHO SV CEA), or both concurrently after
sequential infection of cells with the CEA splice variant then the
full-length CEA (CHO FL+SV CEA); full-length CEA and CEA
splice variant protein expression were verified by western blotting
(Figure S1). As anticipated, MEDI-565 bound to cells expressing
full-length CEA but not to cells expressing the CEA splice variant
(Figure 6A). We note that a higher level of MEDI-565 binding was
observed for cells expressing both the CEA splice variant and full
length CEA together relative to cells expressing only full length
CEA. This is likely due to different levels of expression efficiency in
each independently infected cell line, although effects of the CEA
splice variant protein on full length CEA protein levels or epitope
accessibility in cells cannot be ruled out.
Zhou et al [48] showed that the both the N-terminal domain
and A3 mediated the interaction between CEA molecues on
apposing cell surfaces; both domains are present within the CEA
splice variant. Thus, we tested the hypothesis that co-expression of
the CEA splice variant and full-length CEA proteins may, through
heterophilic interactions, result in the MEDI-565 binding epitope
being masked in the full-length form and subsequently prevent or
reduce MEDI-565 binding. Co-expression of the CEA splice
variant with full-length CEA on the same cells did not significantly
affect the apparent binding affinity of MEDI-565 to full-length
CEA (CHO FL CEA, apparent KD=5.060.15 nM; CHO
FL+SV CEA, apparent KD=5.663.0 nM; p=0.86). These
results were expected since homophilic interactions between full-
length CEA proteins also do not appear to prevent the binding of
MEDI-565 [17,18] or other CEA-specific BiTE antibodies [16].
Consistent with the MEDI-565 binding data, CHO SV CEA
did not trigger the activation of T cells from healthy donors in the
presence of MEDI-565, as measured by the up-regulation of the
IL-2Ra chain/CD25 protein on either CD8 or CD4 T cells
(Figure 6C and D). This T cell activation marker has been shown
previously to correlate temporally with the release of cytokines
from T cells activated by MEDI-565[18] and other BiTE
antibodies [23,25]. Likewise MEDI-565 also did not mediate the
lysis of target cells expressing the splice variant (Figure 6B). In
contrast, MEDI-565 activated T cells and induced killing of CHO
FL CEA or CHO FL+SV CEA cells with similar levels of potency
(EC50 values: CHO FL CEA, EC50=75635 ng/mL; CHO
FL+SV CEA, EC50=59643 ng/mL; p=0.79). Somewhat higher
maximal T cell activation and maximum achievable cytotoxicity
levels were observed with CHO FL+SV CEA cells relative to
CHO FL CEA cells, and may be explained by the higher full
length CEA expression in the former, as described above.
Studies with full length CEA and the splice variant were carried
out in CHO cells due to their ease of infection with lentiviral
constructs and their subsequent selection of CEA-expressing cells
using flow cytometry. To demonstrate the killing specificity of
MEDI-565 for CEA positive human tumor cells, we examined
numerous human cancer cell lines for CEA expression and for
their ability to be killed by MEDI-565 activated T cells. Consistent
with the specificity observed for CHO cells, MEDI-565 mediated
the killing of human tumor cells that expressed CEA, but not those
that did not express cell surface CEA (Figure S2). Additionally, a
control BiTE did not induce T cell lysis of CEA positive or
negative cell lines.
Discussion
To provide insights for CEA-targeted diagnostics and therapy
and understand the specificity of anti-CEA mAbs, many efforts
have been made to characterize the binding epitopes of these
antibodies using various approaches [49,50,51,52]. The most
extensive investigations involve the classification of 52 anti-CEA
mAbs into five distinct epitopes, Gold epitopes 1–5, by competitive
binding analysis [50]. Further studies have correlated the Gold
epitopes to the domains of CEA using different CEA fragment
constructs [51,53,54], however there is no precise localization of
the epitopes to the amino acid sequence level. An attempt to
identify the amino acid sequences corresponding to Gold epitopes
using synthetic overlapping fifteen-mer peptides has failed [55],
suggesting that the Gold epitopes are conformational. In addition,
immunohistochemistry and immuno flow cytometry were used to
demonstrate a good correlation between the Gold epitope groups
and their binding specificity: 1) mAbs that bind to Gold epitopes 2
and 3 were generally specific to CEA, reacting only with colon
carcinoma, normal colon mucosa and normal gastric foveola; 2)
mAbs in epitopes 4 and 5 were highly cross-reactive with different
normal tissues possibly due to binding to CEA-related antigens;
and 3) both specific and cross-reactive mAbs were found in epitope
1 [56]. We have mapped the epitope of the CEA-specific arm of
MEDI-565 to the A2 domain comprised of two stretches of amino
acids, 326–349 and 388–410. Interestingly, the MEDI-565 epitope
on CEA belongs to the Gold epitope 2, which has been localized in
the A2-B2 domains [53] and identified as a CEA-specific epitope
group [56].
CEA comprises highly repetitive immunoglobulin domains of
A1-B1, A2-B2, and A3-B3. Some anti-CEA mAbs bind repetitive
epitopes of CEA [51] and some are highly cross-reactive, lacking
specificity to CEA [56]. The anti-CEA arm of MEDI-565 is a
humanized version of the murine antibody A5B7, which has been
shown to specifically bind to CEA [40,56]. Characterizing the
epitope of MEDI-565 has led us to propose that the critical
residues F
326,T
328, and N
333 mediate the fine specificity to CEA of
MEDI-565 due to their uniqueness in the A2 domain of CEA
when compared with all other immunoglobulin domains of CEA
and other related molecules of the CEACAM family, including
CEACAM1, CEACAM3, CEACAM4, CEACAM6, CEACAM7,
and CEACAM8.
After identifying the binding epitope of MEDI-565, we
evaluated the impact of polymorphisms and isoforms in the A2
domain of CEA on the activity of MEDI-565. Two non-
synonymous SNPs were identified in the binding epitope of
MEDI-565 but occurred at a very low frequency in the general
population and were considered to have little or no impact on
MEDI-565 binding to CEA. In addition, a single splice variant was
identified lacking a portion of the A2 domain critical for MEDI-
565 binding. Efforts to understand the association of splice variant
expression to disease found that its expression occurred in a
substantial percentage of primary human colorectal and gastro-
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tumors in a pattern that was concordant with full length CEA
expression. However, since MEDI-565 did not bind the CEA
splice variant due to loss of the antibody-binding epitope, it was
clear that the splice variant itself is not a target for MEDI-565 in
primary human tumors that also express full length CEA. Because
CEA could participate in homotypic interactions on adjacent cells,
it remained possible that expression of the CEA splice variant may
interfere with the binding of MEDI-565 and the subsequent tumor
cell lysis through its interaction with full length CEA. By co-
expressing the CEA splice variant with full length CEA, we
formally demonstrated that this was not the case, as MEDI-565
binding to full length CEA and potency of CEA-directed lysis were
not significantly affected by simultaneous expression of the splice
variant and full length CEA. Therefore, the expression of the CEA
splice variant by primary human tumor cells is not anticipated to
interfere with MEDI-565 binding to full-length CEA, nor should it
inhibit MEDI-565-mediated T-cell killing of tumor cells expressing
full-length CEA. However, discrimination of full-length CEA from
the CEA splice variant may be important while monitoring the
status of CEA positive tumors via changes in serum CEA levels in
clinical study patients that receive MEDI-565.
Supporting Information
Figure S1 Western blot of CEA protein expressed by CHO cell
lines. The full-length CEA protein is indicated by a filled
arrowhead, and the CEA splice variant by an open arrowhead;
both proteins were detected using a CEACAM5-specific mAb.
Molecular weights (kilodaltons; KDa) of the protein standard are
indicated to the left of the image. Lanes of CHO FL and CHO
FL+SV cell lysates contain a band at ,100 kDa that is presumed
to be a non-glycosylated form of CEA. Equal amounts of protein
loaded into each lane of the gel were controlled by detecting
Figure 6. Role of the CEA splice variant in MEDI-565 mediated T cell activation and target cell killing. A, expression of full-length CEA
and CEA splice variant proteins in CHO cells as determined by flow cytometry. Mouse IgG1, mouse IgG1 control antibody. B, CHO DHFR-, CHO FL,
CHO SV and CHO FL+SV cells were tested for their susceptibility to be killed by CD3+ T cells from 3 individual donors in the presence of MEDI-565 at
the indicated concentrations. EC50 values listed indicate the mean value among 3 donors6standard error of the mean. p=0.79 comparing
cytotoxicity EC50 values between CHO FL CEA and CHO FL+SV CEA cells. C, activation (increased cell surface CD25/IL-2R levels) of CD8+ T cells and D,
activation of CD4+ T cells isolated from each of the 3 healthy donors was investigated concurrently with the cytotoxicity assays shown in panel B.
p=0.60 comparing CD8+ T cell activation EC50 values between CHO FL CEA and CHO FL+SV CEA; p=0.15 comparing CD4+ T cell activation EC50
values between CHO FL CEA and CHO FL+SV CEA. MFI CD25-APC=mean fluorescence intensity of bound APC labeled, anti-human CD25 mAb.
Experiment was repeated once with similar results.
doi:10.1371/journal.pone.0036412.g006
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PLoS ONE | www.plosone.org 12 May 2012 | Volume 7 | Issue 5 | e36412GAPDH. CHO DHFR-, parental CHO cells; CHO FL CEA, full-
length CEA-expressing CHO; CHO SV CEA, CEA splice variant
expressing CHO; CHO FL+SV CEA, CHO cells co-expressing
full-length and splice variant CEA.
(TIF)
Figure S2 MEDI-565 mediated binding to and T cell lysis of
CEA positive, but not CEA negative, human cancer cell lines. A,
flow cytometry analysis of MEDI-565 binding to CEA positive
(H727 and HPAF-II) and CEA negative (A2780 and Colo205)
human cancer cell lines; MFI, mean fluorescence intensity of
AlexaFluorH 488 anti-penta-His secondary antibody bound to
MEDI-565. B, Lack of CEA-negative tumor cell killing by T cells
engaged by MEDI-565 or control BiTE. Percent control
represents degree of specific cell killing, as measured by release
of cellular caspase 3, above that of untreated T cells plus target
cells (set at 100%). C, Killing of CEA positive tumor cells by
MEDI-565 but not by the control BiTE.
(TIF)
Table S1 Ct values for full-length (FL) CEA and CEA splice
variant (SV) cDNA expression in A, pancreas; B, colon; C, breast;
D, lung; E, gastrointestinal tissues.
(PPT)
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